Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 10/20 | 0.47 |
| ▸ | RARB | P10826 | 10/20 | 0.47 |
| ▸ | RARG | P13631 | 10/20 | 0.47 |
| ▸ | RXRA | P19793 | 7/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6430446 | 0.85 | RARB (0.64) | RARARARBRARGRXRACYP26A1 | |
| SCHEMBL8703833 | 0.82 | RARA (0.55) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL8328531 | 0.76 | RARA (0.44) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL6017426 | 0.75 | RARA (0.47) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL8704034 | 0.73 | RARA (0.48) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL8703356 | 0.73 | RARA (0.48) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL6146438 | 0.73 | RARA (0.51) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL7224462 | 0.73 | RARB (0.57) | RARARARBRARGRXRASSTR5 | |
| SCHEMBL8690742 | 0.72 | RARB (0.49) | RARARARBRARGCYP3A4KMT2A | |
| SCHEMBL9185721 | 0.71 | RARA (0.53) | RARARARBRARGRXRASSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627652-B1 | Treatment of diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid | ALLERGAN, INC. | 2003-09-30 | — | — | US | disclosed |
| US-6624188-B1 | Administered to treat or prevent one or more of the diseases and conditions selected from the group consisting of dermatoses, atherosclerosis and restenosis resulting from neointimal hyperproliferation, non-malignant and | ALLERGAN, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-0682516-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| US-5455265-A | For mammals; skin disorders, cancer, inflammatory disease, cardiovascular diorders, autoimmune diseases and others | ALLERGAN, INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994017796-A1 | THERAPEUTIC USE OF COMPOUNDS HAVING SELECTIVE AGONIST-LIKE ACTIVITY ON RXR RETINOID RECEPTORS | ALLERGAN, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5324840-A | Skin disorders | ALLERGAN, INC. (US) | 1994-06-28 | — | — | US | disclosed |